SGS IS PLEASED TO ANNOUNCE THE ACQUISITION OF T...
SGS /
SGS IS PLEASED TO ANNOUNCE THE ACQUISITION OF THE M-SCAN GROUP.
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
M-Scan is a world leading group of chemical analysis laboratories specialized in
advanced chemical and biochemical testing as well as high-end GLP/GMP contract
analytical services, consultancy and training based on Mass Spectrometry and
Chromatography.
M-Scan's laboratories provide analytical services in the area of Life Science,
including protein/glycoprotein analysis, pharmaceutical analysis,
extractables/leachables and bioanalysis to support the drug development program.
M-Scan Ltd was founded as an independent company in 1979 by Professor Howard R.
Morris FRSÂ (Imperial College London).
The M-Scan group currently consists of four laboratories supported by marketing
offices in Europe together with agents in Korea, India and Singapore. It employs
61 highly qualified and recognized experts and generated 2009 revenue in excess
of GBP 6.9 mio.
"This acquisition clearly complements our vision to become one of the top
players within the Biologics testing arena (large molecules) said Chris Kirk,
CEO of SGS.
"The acquisition of M-Scan is a milestone in the implementation of our strategy
to take advantage of the on-going, high-growth development of vaccines and
monoclonal antibodies. M-Scan's global recognition, and expertise together with
it's geographic footprint combined with the existing advanced analytical
services in SGS Life Science provides an excellent platform for further growth
and development.
M-Scan founder, Howard Morris, comments "We see compelling synergies between the
respective current testing activities of M-Scan and SGS and an exciting
opportunity to provide our customers with an enhanced range of services
complementing our core strengths in advanced mass spectrometric and
chromatographic analysis in the fields of biopharmaceutical characterization,
oil/petroleum analysis and environmental monitoring."
ABOUT SGS
The SGS Group is the global leader and innovator in inspection, verification,
testing and certification services. Founded in 1878, SGS is recognized as the
global benchmark in quality and integrity. With 59'000 employees, SGS operates a
network of over 1'000 offices and laboratories around the world.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jean-Luc de Buman
Corporate Communications & Investor Relations
SGS SA
1 place des Alpes
CH 1211 Geneva 1
Tel: Â Â Â Â Â +41 (22) 739 95 93
Fax:Â Â Â Â +41 (22) 739 98 61
SGS.Investor.Relations@sgs.com
WWW.SGS.COM
[HUG#1457452]
--- End of Message ---
SGS
1 place des Alpes<br>P.O. Box 2152 Geneva 1 Switzerland
ISIN: CH0002497458;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SGS via Thomson Reuters ONE
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.